Ghostwriters, data manipulation and dollar diplomacy: how drug companies pull the strings in clinical research.
Berger
Eric
E
D001319:Authorship; D002986:Clinical Trials as Topic / Q000191:economics* / Q000941:ethics / Q000331:legislation & jurisprudence / Q000592:standards; D016265:Conflict of Interest / Q000191:economics*; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects; D030881:Disclosure / Q000592:standards; D004345:Drug Industry / Q000191:economics* / Q000331:legislation & jurisprudence; D035081:Editorial Policies; D033161:Government Regulation; D007783:Lactones / Q000009:adverse effects; D010506:Periodicals as Topic / Q000592:standards; D017594:Publication Bias / Q000706:statistics & numerical data; D012109:Research Support as Topic / Q000941:ethics / Q000331:legislation & jurisprudence / Q000639:trends; D013450:Sulfones / Q000009:adverse effects; D014481:United States
D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib